- Home
- PHGE vs ABTS Comparison
PHGE vs ABTS Comparison
Compare PHGE & ABTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHGE
- ABTS
- Stock Information
- Founded
- PHGE 2015
- ABTS 2010
- Country
- PHGE Israel
- ABTS Hong Kong
- Employees
- PHGE N/A
- ABTS N/A
- Industry
- PHGE Biotechnology: Pharmaceutical Preparations
- ABTS Computer Software: Programming Data Processing
- Sector
- PHGE Health Care
- ABTS Technology
- Exchange
- PHGE Nasdaq
- ABTS Nasdaq
- Market Cap
- PHGE 11.0M
- ABTS 9.8M
- IPO Year
- PHGE N/A
- ABTS N/A
- Fundamental
- Price
- PHGE $0.39
- ABTS $4.70
- Analyst Decision
- PHGE Strong Buy
- ABTS
- Analyst Count
- PHGE 1
- ABTS 0
- Target Price
- PHGE $15.00
- ABTS N/A
- AVG Volume (30 Days)
- PHGE 3.0M
- ABTS 47.0K
- Earning Date
- PHGE 08-13-2025
- ABTS 08-16-2025
- Dividend Yield
- PHGE N/A
- ABTS N/A
- EPS Growth
- PHGE N/A
- ABTS N/A
- EPS
- PHGE N/A
- ABTS N/A
- Revenue
- PHGE N/A
- ABTS $6,711,225.00
- Revenue This Year
- PHGE N/A
- ABTS N/A
- Revenue Next Year
- PHGE N/A
- ABTS N/A
- P/E Ratio
- PHGE N/A
- ABTS N/A
- Revenue Growth
- PHGE N/A
- ABTS 299.11
- 52 Week Low
- PHGE $0.34
- ABTS $1.35
- 52 Week High
- PHGE $3.48
- ABTS $14.10
- Technical
- Relative Strength Index (RSI)
- PHGE 37.11
- ABTS 58.05
- Support Level
- PHGE $0.38
- ABTS $4.82
- Resistance Level
- PHGE $0.77
- ABTS $5.50
- Average True Range (ATR)
- PHGE 0.06
- ABTS 0.60
- MACD
- PHGE -0.00
- ABTS 0.06
- Stochastic Oscillator
- PHGE 6.52
- ABTS 64.31
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).
About ABTS Abits Group Inc
Abits Group Inc is a digital data center operator with bitcoin self-mining operations. The group has its subsidiaries in USA, China, Canada and Hong Kong.